Healthcare IT News - Telehealth
MAY 29, 2020
According to the analysis by Frost & Sullivan, non-contact patient monitoring technologies are gravitating toward the use of video, sound analysis and mobile-based platforms incorporating advanced technologies such as machine learning and artificial intelligence (AI) algorithms. THE LARGER CONTEXT.
Digital Health Global
JANUARY 10, 2024
Key Highlights of the Partnership: 1) Expanding Indications : The partnership will harness TNL’s AI Digital Cells Lab platform to explore additional indications for one of Debiopharm’s cancer drugs. Debiopharm’s main activities include drug development, drug manufacturing and digital health investment.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Digital Health Global
APRIL 5, 2024
Furthermore, the industry witnessed a decline in the average return on investment (ROI) for R&D to as low as 1.2%, and the peak sales per asset valued just above $350 million, indicating a need to build more efficient drug development processes with the implementation of newer technologies.
Digital Health Global
SEPTEMBER 19, 2023
Among these transformative innovations, artificial intelligence (AI ) stands out as a major force, reshaping the fields of drug discovery , drug development, clinical trials and patient care. AI algorithms come into play in this complexity by orchestrating the analysis of intricate molecular dynamics.
Healthcare IT Today
APRIL 25, 2024
In our interview, Gil emphasizes the critical role of AI in expediting the discovery of new drugs, citing the lengthy and costly nature of traditional drug development processes. However, with AI-driven approaches, Aion Labs is paving the way for a paradigm shift in drug discovery.
Digital Health Global
MAY 10, 2023
Enhancing outcomes for patients with the implementation of digital technologies, such as artificial intelligence (AI) and big data analysis, empowers healthcare professionals to make better-informed decisions. Artificial Intelligence is utilized in various areas of healthcare, ranging from drug development to medical image analysis.
Digital Health Global
MARCH 29, 2023
With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drug development, patient care and new drug discovery,” said Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis. “We
Expert insights. Personalized for you.
149 
Let's personalize your content